 |
Indication & Dosage |
| |
| |
| Oral |
| BRAIN TUMOURS |
| Adult:
100-130 mg/m2 as a single dose every 6 wk. Readjust dose according to platelet and leukocyte counts. Compromised marrow function: 100 mg/m2 as a single dose every 6 wk. |
| |
| Oral |
| BRAIN TUMOURS |
| Child:
75-150 mg/m2 as a single dose every 6 wk. Readjust dose according to platelet and leukocyte counts. |
| |
| Oral |
| HODGKIN'S DISEASE, RESISTANT OR RELAPSED |
| Adult:
100-130 mg/m2 as a single dose every 6 wk. Readjust dose according to platelet and leukocyte counts. Compromised marrow function: 100 mg/m2 as a single dose every 6 wk. |
| |
| Oral |
| HODGKIN'S DISEASE, RESISTANT OR RELAPSED |
| Child:
75-150 mg/m2 as a single dose every 6 wk. Readjust dose according to platelet and leukocyte counts. |
| |
| Oral |
| MALIGNANT MELANOMA |
| Adult:
100-130 mg/m2 as a single dose every 6 wk. Readjust dose according to platelet and leukocyte counts. Compromised marrow function: 100 mg/m2 as a single dose every 6 wk. |
| |
| Oral |
| MALIGNANT MELANOMA |
| Child:
75-150 mg/m2 as a single dose every 6 wk. Readjust dose according to platelet and leukocyte counts. |
| |
| Oral |
| LUNG CANCER |
| Adult:
100-130 mg/m2 as a single dose every 6 wk. Readjust dose according to platelet and leukocyte counts. Compromised marrow function: 100 mg/m2 as a single dose every 6 wk. |
| |
| Oral |
| LUNG CANCER |
| Child:
75-150 mg/m2 as a single dose every 6 wk. Readjust dose according to platelet and leukocyte counts. |
|
| |
|
| Administration |
Should be taken on an empty stomach (i.e. At least one hour before food or four hours after food). (Take on an empty stomach. May be taken at bedtime to reduce occurrence of nausea.) |
| |
|
| Precautions |
Monitor CBC with differential platelet count wkly for at least 6 wk after a dose. Periodically perform pulmonary function studies and LFTs. |
| |
|
Potentially Life-threatening
Adverse Drug Reactions |
Pulmonary infiltrates, pulmonary fibrosis, nausea, vomiting, hepatotoxicity, nephrotoxicity, stomatitis, alopecia, disorientation, lethargy, dysarthria, ataxia, visual disturbances. |
| |
|
| Adverse Drug Reactions |
Delayed bone marrow suppression and permanent marrow damage following prolonged use. |
| |
|
| Interactions |
Increased levels/effects with CYP2D6 inhibitors. |
| |
|
|
|
